Lou Whiteman

I like the company.

The growth phase is over.

What are you left with?

Yeah.

It's a terrible joke here.

Who knew the GLP-1s were slimming for a Novo Nordisk?

Does anyone not have a GLP-1 at this point?

Pricing headwinds in an increasingly competitive market.

How many times was that said?

You talk about the restaurant stocks, how often was GLP-1s said in their calls.

How often was just pricing headwinds said on the Norvo?

The oral was supposed to be the solution here.

But if you look at it, it's 2.4 milligrams versus 25 milligrams for the oral.

That's 10x the amount of active ingredient.

I'm curious, we're seeing margins fall.

How much of that is just startup here and how much of that is somewhat permanent if they do, quote unquote, succeed in moving people to the oral version?

What does that do to profitability?

That seems like a slippery slope as far as that being the answer.

I don't know if Novo has a good answer right here.

And as you say, it's only going to get more competitive from here.